One item dealt with whether the outcome of interest was present at the start of the study, which was a difficult topic for a study of anti-VEGF efficacy on DME, partly because of the fluctuating nature of the macular edema and partly because many studies evaluated the effect of switching therapy from another agent, which presumably had a certain level of efficacy. The gene discussed is VEGFA; the disease is macular retinal edema.